NCT05237739

Brief Summary

Periodontitis, a microbially-driven inflammatory disease has been shown to be the sixth most common disease of mankind. The 2009 UK Adult Dental Health Survey found that 54% of adults experience gum bleeding (gingivitis) with 45% of these suffering from periodontitis. Periodontitis begins at the gingival margins of teeth and over time, in susceptible individuals, the presence of a plaque biofilm can lead to the loss of the supporting connective tissue and alveolar bone associated with the teeth. This leads to the formation of a pathological periodontal pocket between the gingiva and tooth root, measurable by the use of a periodontal probe and recorded as the probing pocket depth (PPD). The associated loss of alveolar bone support is measurable radiographically and often leads to tooth mobility and if allowed to persist, can eventually lead to tooth loss. Periodontitis is classified into 4 stages (I-IV) based on disease severity and 3 grades (A-B-C) based on risk of disease progression. The treatment of periodontitis involves a non-specific reduction of the bacterial load below the gingival margin. This is achieved by effective oral hygiene procedures and non-surgical periodontal therapy (NSPT), both of which are aimed at the removal of calculus (tartar) deposits and the disruption of the plaque biofilm from the affected root surfaces. In some cases, this treatment may then be followed by more invasive treatments such as periodontal surgery and if successful, patients can then be followed and maintained with supportive periodontal maintenance therapy (SPT). It should be noted that certain periodontal lesions in some patients do not however always respond favourably to treatment.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Feb 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 24, 2022

Completed
12 days until next milestone

Study Start

First participant enrolled

February 5, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

February 14, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2024

Completed
Last Updated

February 6, 2024

Status Verified

February 1, 2024

Enrollment Period

2.1 years

First QC Date

January 24, 2022

Last Update Submit

February 5, 2024

Conditions

Outcome Measures

Primary Outcomes (6)

  • Number of patients

    Number of participants recruited and retained into the study

    13 months

  • Number of responsive and non-responsive

    Number of participants deemed responsive and non-responsive to different treatments. Questionnaire will be used to assess the responsiveness to each treatment.

    13 months

  • Number of participants randomised

    Number of participants willing to be randomised to treatment II of the study (if deemed non-responsive following treatment I). Yes or Not answer to randomisation will be used to assess this number.

    13 months

  • patient-reported outcomes (Pros)

    A self-administered questionnaire will be used to assess the patient-reported outcomes (PROS) at 6 and 12 months based on different treatment arms

    13 months

  • Probing Pocket Depth (PPD)

    Distance between gingival margin and the bottom of the pocket, measured in mm

    13 months

  • Bleeding on probing (BOP)

    Bleeding after probing with the periodontal probe the gingival margin, 0 no bleeding 1 bleeding.

    13 months

Secondary Outcomes (1)

  • Microbiological analysis

    13 months

Study Arms (2)

Test Group

EXPERIMENTAL

Ten participants will be randomised to receive surgical periodontal treatment in the form of open flap debridement (OFD).

Procedure: Open Flap Debridement (OFD)

Control Group

ACTIVE COMPARATOR

Ten participants will be randomised to receive non-surgical periodontal treatment (NSPT). All treatment will be carried out by the same therapist, including oral hygiene.

Procedure: Non-Surgical Periodontal treatment (NSPT)

Interventions

Participants will receive local anesthesia. Thorough debridement of the root surface will be completed to the depth of the periodontal pocket and of the furcation lesion, by using piezo-electric/ultrasonic devices with specific thin and delicate tips (such as Cavitron, Dentsply Sirona, US) and/or curettes. Treatment chair time will be recorded for each visit.

Control Group

Patients will receive local anesthesia and intrasulcular incisions will be made by buccal and lingual/palatal aspects in order to reflect full-thickness flaps. After reflection of the flaps, the granulation tissue around the tooth will be removed with the non-cutting edge of a suitable scaling instrument such as a curette, taking care not to damage the root surfaces. Thorough debridement of the furcation area will be carried out by using piezo-electric/ultrasonic devices with specific thin and delicate tips

Test Group

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18-70
  • Diagnosis of Periodontitis stage III or IV, grade A, B or C
  • At least one maxillary or mandibular molars with:
  • Furcation involvement grade III horizontal classification degree B-C vertical classification without any ongoing restorative problems as judged by the study clinician)
  • Probing depth ≥ 6mm
  • Mobility \< degree II (as examined by the study clinician)
  • Absence of any ongoing endodontic pathology (as examined by the study clinician)
  • Absence of an adjacent tooth with unfavorable periodontal prognosis (as judged by the study clinician)
  • Non-surgical periodontal therapy performed to the study site within the last 6 months.
  • Able to consent to study participation

You may not qualify if:

  • Smoking (any current or in past 5 years)
  • Medical history including diabetes or hepatic or renal disease, or other serious medical conditions or transmittable diseases
  • History of conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures
  • Anti-inflammatory or anticoagulant therapy during the month preceding the baseline exam
  • Systemic antibiotic therapy during the 3 months preceding the baseline exam
  • History of alcohol or drug abuse
  • . Self-reported pregnancy or lactation
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that according to the investigator may increase the risk associated with trial participation
  • Previous surgical periodontal performed to the study site.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

King's College London

London, United Kingdom

Location

MeSH Terms

Conditions

Furcation DefectsPeriodontitisAlveolar Bone Loss

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic DiseasesBone ResorptionBone DiseasesMusculoskeletal DiseasesPeriodontal Atrophy

Study Officials

  • Luigi Nibali

    Floor 18, Tower Wing Guy's Hospital London SE1 9RTN/A

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Simple randomisation will be completed using the online programme, Sealed Envelope. This will be completed by a member of the research team not involved in this specific study. Sealed Envelope will provide a randomisation schedule, patient numbering and a sequence of patient number assignment. This will all be safely stored and secured. The treatment allocation will be communicated to the study therapist/nurse and patient when booking the treatment appointment. It will not be possible to blind the participants or the clinician completing the study treatment. The study examiner will remain blind to treatment allocation.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This is a single-centre single-masked randomised controlled feasibility trial with SMART design to assess the response to treatment for degree III periodontal furcation involved molars (n=20).
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 24, 2022

First Posted

February 14, 2022

Study Start

February 5, 2022

Primary Completion

March 1, 2024

Study Completion

March 1, 2024

Last Updated

February 6, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share

Locations